Comparative evaluation of radionuclide therapy using 90Y and 177Lu.
Ann Nucl Med
; 37(1): 52-59, 2023 Jan.
Article
in En
| MEDLINE
| ID: mdl-36352185
ABSTRACT
OBJECTIVE:
Both 90Y and 177Lu are attractive ß-emitters for radionuclide therapy and have been used in clinical practice. Nevertheless, comparative evaluation between 90Y- and 177Lu-labeled molecules has not been fully conducted. Thus, in this study, the features of 90Y and 177Lu for radionuclide therapy were assessed in tumor-bearing mice.METHODS:
Two tumor cell lines with different growth rates were used. Biodistribution studies of 177Lu-labeled antibodies (177Lu-Abs) were conducted in each tumor-bearing mouse model. Subsequently, the therapeutic effect of 90Y- and 177Lu-Ab were assessed in tumor-bearing mice. The absorbed radiation dose for the tumor was estimated using the Monte Carlo simulation.RESULTS:
177Lu-Abs demonstrated high tumor accumulation in both tumor-xerograph. In the fast-growing tumor model, 90Y-Ab showed a better therapeutic effect than 177Lu-Ab, reflecting a higher absorbed radiation dose of 90Y-Ab than that of 177Lu-Ab. In the slow-growing tumor model, both 90Y- and 177Lu-Ab showed an excellent therapeutic effect; however, 177Lu-Ab had a longer efficacy period than 90Y-Ab, which could be attributed to the longer half-life and better dose uniformity of 177Lu than those of 90Y.CONCLUSIONS:
To accomplish a maximum therapeutic effect, selecting 90Y or 177Lu, to depend on the growth rate of individual cancer, would be helpful.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Radioisotopes
/
Lutetium
Limits:
Animals
Language:
En
Journal:
Ann Nucl Med
Journal subject:
MEDICINA NUCLEAR
Year:
2023
Document type:
Article
Affiliation country:
Japan